Coeptis Therapeutics Holdings Inc
For the period ended Sep 30, 2024. Filed Nov 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 13, 2024
ZSQR$2.30-17.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
For the Three and Nine Months Ended September 30, 2024 and 2023
| PREFERRED STOCK · COMMON STOCK · ADDITIONAL PAID-IN · SHARES · SUBSCRIPTION · ACCUMULATED · TOTAL COEPTIS · NON- CONTROLLING · TOTAL | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| SHARES | AMOUNT | SHARES | AMOUNT | CAPITAL | SUBSCRIBED | RECEIVABLE | DEFICIT | EQUITY | INTERESTS | EQUITY | |
| BALANCE AT DECEMBER 31, 2022 | – | $– | 19,566,839 | $1,957 | $70,541,095 | $– | $– | $(66,089,723) | $4,453,329 | $– | $4,453,329 |
| Shares subscribed for non-employee services | – | – | 1,374,197 | 137 | 2,396,677 | 720,000 | – | – | 3,116,814 | – | 3,116,814 |
| Warrants issued for services | – | – | – | – | 1,111,706 | – | – | – | 1,111,706 | – | 1,111,706 |
| Stock based compensation | – | – | – | – | 122,391 | – | – | – | 122,391 | – | 122,391 |
| Net loss | – | – | – | – | – | – | – | (7,957,833) | (7,957,833) | – | (7,957,833) |
| BALANCE AT MARCH 31, 2023 | – | $– | 20,941,036 | $2,094 | $74,171,869 | $720,000 | $– | $(74,047,556) | $846,407 | $– | $846,407 |
| Shares subscribed for non-employee services | – | – | 700,000 | 70 | 1,070,930 | (720,000) | – | – | 351,000 | – | 351,000 |
| Warrants issued for services | – | – | – | – | 811,500 | – | – | – | 811,500 | – | 811,500 |
| Stock based compensation | – | – | – | – | 113,301 | – | – | – | 113,301 | – | 113,301 |
| Issuance of common stock and warrants, net of issuance costs | – | – | 2,755,000 | 276 | 3,040,585 | – | – | – | 3,040,861 | – | 3,040,861 |
| Net loss | – | – | – | – | – | – | – | (3,202,620) | (3,202,620) | – | (3,202,620) |
| BALANCE AT JUNE 30, 2023 | – | $– | 24,396,036 | $2,440 | $79,208,185 | $– | $– | $(77,250,176) | $1,960,449 | $– | $1,960,449 |
| Shares issued for cash | – | – | 500,000 | 50 | 499,950 | – | – | – | 500,000 | – | 500,000 |
| Shares issued in exchange for subscription receivable | – | – | 2,500,000 | 250 | 2,499,750 | – | (2,500,000) | – | – | – | – |
| Shares issued for services | – | – | 550,000 | 54 | 531,746 | – | – | – | 531,800 | – | 531,800 |
| Warrants issued for services | – | – | – | – | 514,819 | – | – | – | 514,819 | – | 514,819 |
| Stock based compensation | – | – | – | – | 113,301 | – | – | – | 113,301 | – | 113,301 |
| Issuance of common stock and warrants, net of issuance costs | – | – | 745,000 | 75 | – | – | – | – | 75 | – | 75 |
| Shares issued for the conversion of debt | – | – | 300,000 | 30 | 302,896 | – | – | – | 302,926 | – | 302,926 |
| Shares issued in connection with asset purchase agreement | – | – | 4,000,000 | 400 | 4,319,600 | – | – | – | 4,320,000 | – | 4,320,000 |
| Net loss | – | – | – | – | – | – | – | (6,350,494) | (6,350,494) | – | (6,350,494) |
| BALANCE AT SEPTEMBER 30, 2023 | – | $– | 32,991,036 | $3,299 | $87,990,247 | $– | $(2,500,000) | $(83,600,673) | $1,892,873 | $– | $1,892,873 |
COEPTIS THERAPEUTICS HOLDINGS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
For the Three and Nine Months Ended September 30, 2024 and 2023
(Unaudited)
(continued)
| PREFERRED STOCK · COMMON STOCK · ADDITIONAL PAID-IN · SHARES · SUBSCRIPTION · ACCUMULATED · TOTAL COEPTIS · NON- CONTROLLING · TOTAL | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| SHARES | AMOUNT | SHARES | AMOUNT | CAPITAL | SUBSCRIBED | RECEIVABLE | DEFICIT | EQUITY | INTERESTS | EQUITY | |
| BALANCE AT DECEMBER 31, 2023 | – | $– | 35,331,036 | $3,533 | $91,666,691 | $– | $(3,500,000) | $(87,356,260) | $813,964 | $– | $813,964 |
| Shares issued for non-employee services | – | – | 1,096,381 | 110 | 541,640 | – | – | – | 541,750 | – | 541,750 |
| Warrants issued for cash | – | – | – | – | 500,000 | – | – | – | 500,000 | – | 500,000 |
| Warrants issued for services | – | – | – | – | 8,150 | – | – | – | 8,150 | – | 8,150 |
| Warrants issued in exchange for note receivable | – | – | – | – | 1,900,000 | – | (2,000,000) | – | (100,000) | – | (100,000) |
| Stock based compensation | – | – | – | – | 96,889 | – | – | – | 96,889 | – | 96,889 |
| Net loss | – | – | – | – | – | – | – | (3,001,388) | (3,001,388) | – | (3,001,388) |
| BALANCE AT MARCH 31, 2024 | – | $– | 36,427,417 | $3,643 | $94,713,370 | $– | $(5,500,000) | $(90,357,648) | $(1,140,635) | $– | $(1,140,635) |
| Shares issued for services | – | – | 1,850,000 | 185 | 558,165 | – | – | – | 558,350 | – | 558,350 |
| Shares issued for the conversion of debt | 506 | 1 | 1,441,176 | 144 | 951,855 | – | – | – | 952,000 | – | 952,000 |
| Preferred share offering | 3,794 | 1 | – | – | 3,661,505 | 50,000 | (2,100,000) | – | 1,611,506 | 132,494 | 1,744,000 |
| Stock based compensation | – | – | – | – | 611,570 | – | – | – | 611,570 | – | 611,570 |
| Net loss | – | – | – | – | – | – | – | (3,035,345) | (3,035,345) | – | (3,035,345) |
| BALANCE AT JUNE 30, 2024 | 4,300 | $2 | 39,718,593 | $3,972 | $100,496,465 | $50,000 | $(7,600,000) | $(93,392,993) | $(442,554) | $132,494 | $(310,060) |
| Shares issued for services | – | – | 250,000 | 25 | 49,475 | – | – | – | 49,500 | – | 49,500 |
| Preferred share offering | 1,525 | – | – | – | 1,499,810 | (50,000) | – | – | 1,449,810 | 25,190 | 1,475,000 |
| Relief of subscription receivable | – | – | – | – | – | – | 5,500,000 | – | 5,500,000 | – | 5,500,000 |
| Stock based compensation | – | – | – | – | 96,891 | – | – | – | 96,891 | – | 96,891 |
| Net loss | – | – | – | – | – | – | – | (1,828,914) | (1,828,914) | – | (1,828,914) |
| BALANCE AT SEPTEMBER 30, 2024 | 5,825 | $2 | 39,968,593 | $3,997 | $102,142,641 | $– | $(2,100,000) | $(95,221,907) | $4,824,733 | $157,684 | $4,982,417 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.